RECENT DEVELOPMENTS IN THE WORLD’S LEADING GENERIC MARKETS

according to the recent European Generic medicines association estimates, savings within the Eu healthcare expenditure achieved by generic substitution amount to € 30 billion (1). in the course of the past 5 years, some of the leading therapy classes, such as oncologics, antihypertensive, antidiabetics, lipid regulators, antipsychotics, platelet aggregation inhibitors, antiulcerants and few others, experienced fierce generic competition, when blockbuster patents expired (1). in several European countries, such as France, italy and Switzerland, we can observe the landscape of price-regulated markets. market uptake of generics remained weak even after a series of policy measures aimed to improve their prescribing and dispensing (2). Significant delay in generic marketing approvals and particularly lo